Step by step.

Spending on cancer drugs has almost doubled from 2012 to 2016 alone. Stop and think about that for a moment. U Penn authors offer up three common sense steps to combat soaring prices for marginal effects: the FDA should define a minimum threshold for “clinically meaningful,” Medicare should be granted negotiating power, and physicians and patients should employ cost-effectiveness tools in joint decision making. | Bekelman, JAMA 2018